Key Highlights

• EchoIQ (ASX: EIQ) is being assessed against its latest disclosed developments.

• Recent company updates provide the main operational or financial evidence.

• The next phase depends on delivery against stated milestones rather than price movement alone.

• Upcoming company disclosures should provide the clearest evidence of progress.

EchoIQ (ASX: EIQ) has built a more substantial commercial framework around its cardiac artificial-intelligence platform, with funding and distribution now sitting alongside regulatory milestones. The company's recent Partnership with Pro Medicus has become a central feature of the story.

The opportunity is tied to converting those relationships into hospital adoption and recurring revenue. EchoIQ already has an FDA-cleared module, but its next phase depends on further regulatory progress and execution in the US healthcare market.

Fresh Developments

On 25 June 2026, Pro Medicus committed an initial AUD 10mn through secured convertible notes, with another AUD 10mn conditional on FDA clearance of EchoSolv HF. Pro Medicus will also act as a US reseller. EchoIQ appointed Matthew Dodds as CFO and Dr Vinod Thourani as a Clinical Advisor around the same period.

Inside the Business

EchoIQ develops AI software intended to support clinical decision-making in cardiology. Its EchoSolv platform analyses echocardiogram data, with EchoSolv AS focused on aortic stenosis and EchoSolv HF targeting heart failure. EchoSolv AS has received FDA clearance and has been deployed at Mount Sinai in New York.

Why the Story Is Drawing Attention

The Pro Medicus relationship provides both Capital and a potential route into US hospitals. EchoIQ also has a Mayo Clinic collaboration examining cardio-oncology risk stratification. A US reimbursement code for AI-based cardiac imaging analysis was established in April 2026, adding another element to the commercialisation pathway.

Numbers Behind the Story

EchoIQ remains loss-making and does not pay a dividend. The initial Pro Medicus funding expands its resources, while the second AUD 10mn Tranche depends on FDA clearance for EchoSolv HF. The company has also previously used equity-market funding to support its US expansion.

What Could Change the Picture

FDA clearance for EchoSolv HF is the clearest regulatory milestone. New US hospital deployments, billing under the reimbursement code and contract wins would provide commercial evidence. Further Mayo Clinic developments could add clinical support, while the Pro Medicus relationship will show whether the reseller pathway converts into broader market access.

Risks That Still Matter

EchoSolv HF may not receive FDA clearance, and delays could affect funding and expansion plans. EchoIQ's valuation has been sensitive to expectations, while the convertible notes carry 12.5% annual interest and potential dilution considerations. Hospital adoption can also be lengthy and competitive, and the company remains pre-profit.

What Investors Should Watch

FDA progress, quarterly Cash Flow and new US deployments are the main checkpoints. Investors should also follow the Pro Medicus relationship, customer receipts, cash runway and any new capital raising. Evidence of repeatable revenue will be more significant than short-term share-price movements.

What Could Come Next for EchoIQ (ASX: EIQ)?

The next stage will be shaped by the milestones already identified in the company's disclosures. For EIQ, investors can use upcoming operational, financial, regulatory or project updates to assess whether the stated strategy is translating into measurable progress.